Boceprevir for untreated chronic HCV genotype 1 infection

Clicks: 498
ID: 117918
2011
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #23 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 we …
Reference Key
f2011theboceprevir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Poordad F;McCone J;Bacon BR;Bruno S;Manns MP;Sulkowski MS;Jacobson IM;Reddy KR;Goodman ZD;Boparai N;DiNubile MJ;Sniukiene V;Brass CA;Albrecht JK;Bronowicki JP; ;;
Journal The New England journal of medicine
Year 2011
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/21449783
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male middle aged Comparative Study Clinical Trial Phase III Randomized Controlled Trial Double-Blind Method Multicenter Study Genotype viral / blood drug therapy combination antiviral agents / therapeutic use* recombinant proteins viral load ribavirin / therapeutic use hepacivirus / isolation & purification chronic / virology african continental ancestry group antiviral agents / adverse effects hepacivirus / genetics* chronic / drug therapy* interferon alpha-2 serine proteinase inhibitors / adverse effects serine proteinase inhibitors / therapeutic use* pmid:21449783 pmc3766849 doi:10.1056/nejmoa1010494 fred poordad jonathan mccone sprint-2 investigators anemia / chemically induced chronic / ethnology interferon-alpha / therapeutic use polyethylene glycols / therapeutic use proline / adverse effects proline / analogs & derivatives* proline / therapeutic use

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.